Cognitive functions in primary CNS lymphoma after single or combined modality regimens

Neuro-Oncology

Volumn 14, Issue 1, 2012, Pages 101-108

  Correa, Denise D ^a   Shi, Weiji ^a   Abrey, Lauren E ^a   De Angelis, Lisa M ^a   Omuro, Antonio M ^a   Deutsch, Mariel B ^a   Thaler, Howard T ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cognitive; Methotrexate; Neuropsychology; Primary CNS lymphoma; Radiation

Indexed keywords

CYTARABINE; METHOTREXATE; PROCARBAZINE; VINCRISTINE;

ADULT; AGED; ARTICLE; BRAIN ATROPHY; BRAIN LYMPHOMA; CANCER RADIOTHERAPY; CANCER SURVIVOR; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG MEGADOSE; EVALUATION AND FOLLOW UP; FEMALE; HUMAN; MALE; NEUROLOGIC EXAMINATION; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY TUMOR; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; REMISSION; WHITE MATTER; WHOLE BODY RADIATION;

ADULT; AGED; AGED, 80 AND OVER; BRAIN; CENTRAL NERVOUS SYSTEM NEOPLASMS; COGNITION; COGNITION DISORDERS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA; MAGNETIC RESONANCE IMAGING; MALE; METHOTREXATE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; QUALITY OF LIFE;

EID: 84856247948     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor186     Document Type: Article

References (30)

1. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol. 1998;16:859-863. (Pubitemid 28108717)
2. DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002;20:4643-4648. (Pubitemid 36025280)
3. Omuro AM, Ben-Porat LS, Panageas KS, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol. 2005;62:1595-1600. (Pubitemid 41434567)
4. DeAngelis L, Posner JB. Side effects of radiation therapy. In: DeAngelis, L, Posner, JB, eds. Neurologic Complications of Cancer. 2nd ed. New York: Oxford University Press, 2009: 551-555.
5. Monje ML, Vogel H, Masek M, et al. Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Ann Neurol. 2007;62:515-520. (Pubitemid 350308776)
6. Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: A randomised phase 2 trial. Lancet. 2009;374:1512-1520.
7. Omuro A, Taillandier L, Chinot O, et al. Primary CNS lymphoma in patients younger than 60: Can whole-brain radiotherapy be deferred? J Neurooncol. 2010;104:323-330.
8. Gerstner ER, Carson KA, Grossman SA, Batchelor TT. Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology. 2008;70:401-402. (Pubitemid 351653404)
9. Juergens A, Pels H, Rogowski S, et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol. 2010;67:182-189.
10. Illerhaus G, Marks R, Muller F, et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: Results of a prospective pilot and phase II study. Ann Oncol. 2009;20:319-325.
11. Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): A phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11:1036-1047.
12. Ney DE, Reiner AS, Panageas KS, et al. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center experience. Cancer. 2010;116:4605-4612.
13. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol. 2003;21:4483-4488. (Pubitemid 46594017)
14. Behin A, Delattre J-Y. Neurologic sequelae of radiotheray on the nervous system. Totowa, New Jersey: Humana Press Inc., 2003.
15. Correa DD, Maron L, Harder H, et al. Cognitive functions in primary central nervous system lymphoma: Literature review and assessment guidelines. Ann Oncol. 2007;18:1145-1151. (Pubitemid 47244358)
16. Correa DD, DeAngelis LM, Shi W, et al. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology. 2004;62:548-555. (Pubitemid 38252794)
17. Wefel JS, Lenzi R, Theriault RL, et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial. Cancer. 2004;100:2292-2299. (Pubitemid 38657875)
18. Fazekas F, Chawluk JB, Alavi A, et al. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987;149:351-356. (Pubitemid 17104996)
19. Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: Long-term follow-up. Lancet Neurol. 2009;8:810-818.
20. Kuritz SJ, Landis JR, Koch GG. A general overview of Mantel-Haenszel methods: Applications and recent developments. Annu Rev Public Health. 1988;9:123-160. (Pubitemid 19082377)
21. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289-300.
22. Dietrich J, Monje M, Wefel J, Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist. 2008;13:1285-1295.
23. Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004;3:159-168. (Pubitemid 38229950)
24. Spelten ER, Sprangers MA, Verbeek JH. Factors reported to influence the return to work of cancer survivors: A literature review. Psychooncology. 2002;11:124-131. (Pubitemid 34256423)
25. Postma TJ, Klein M, Verstappen CC, et al. Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma. Neurology. 2002;59:121-123. (Pubitemid 34742806)
26. Surma-aho O, Niemela M, Vilkki J, et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology. 2001;56:1285-1290. (Pubitemid 32455284)
27. Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25:4730-4735. (Pubitemid 350086474)
28. CorreaDD, Rocco-Donovan M, DeAngelisLM, et al. Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol. 2009;91:315-321.
29. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034-5043. (Pubitemid 46224010)
30. Gehring K, Sitskoorn MM, Aaronson NK, Taphoorn MJ. Interventions for cognitive deficits in adults with brain tumours. Lancet Neurol. 2008;7:548-560. (Pubitemid 351657495)